Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

Sian Faustini, Adrian Shields, Gemma Banham, Nadezhda Wall, Saly Al-Taei, Chloe Tanner, Zahra Ahmed, Elena Efstathiou, Neal Townsend, Margaret Goodall, Tim Plant, Marisol Perez-Toledo, Aleksandra Jasiulewicz, Ruth Price, James McLaughlin, John Farnan, Julie Moore, Louise Robertson, Andrew Nesbit, Grace CurryAmy Black, Adam Cunningham, Lorraine Harper, Tara Moore, Mark Drayson, Alex Richter

Research output: Contribution to journalLetterpeer-review

Abstract

Highlights
• IgG anti-SARS-CoV-2 Omicron spike glycoprotein antibodies were detected in 100% of health care workers, a real world population attending general practice for vaccination and haemodialysis patients 4 weeks after a third SARS-CoV-2 vaccine dose (Pfizer-BioNtech 162b2).
• Against both Delta and Omicron variants, antibody levels were higher in the cohort who had previously received two doses of AstraZeneca ChAdOx1 nCoV-19 vaccine than two doses of Pfizer-BioNtech 162b2.
• Prior to this third vaccine dose and 6 months post second vaccine dose, there was evidence of significant waning of antibody reactivity against Delta and Omicron variants of concern, particularly in individuals initially receiving two doses of AstraZeneca ChAdOx1 nCoV-19.
Original languageEnglish
JournalJournal of Infection
DOIs
Publication statusE-pub ahead of print - 10 Jan 2022

Keywords

  • COVID-19
  • SARS-CoV-2
  • Haemodialysis
  • Chronic kidney disease
  • Vaccination
  • antibody response
  • Variants of Concern
  • Cross reactivity
  • Delta
  • Omicron

Fingerprint

Dive into the research topics of 'Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals'. Together they form a unique fingerprint.

Cite this